Gast Kelly C, Benedict Jason A, Grogan Madison, Janse Sarah, Saphire Maureen, Kumar Pooja, Bertino Erin M, Agne Julia L, Presley Carolyn J
Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States.
Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Front Oncol. 2022 Feb 28;12:835881. doi: 10.3389/fonc.2022.835881. eCollection 2022.
Palliative care is beneficial for patients with advanced lung cancer, but the optimal model of palliative care delivery is unknown. We investigated healthcare utilization before and after embedding a palliative care physician within a thoracic medical oncology "onco-pall" clinic.
This is a retrospective cross-sectional cohort study comparing healthcare outcomes in two cohorts: "pre-cohort" 12 months prior to and "post-cohort" 12-months after the onco-pall clinic start date. Patients were included if they had a new diagnosis of lung cancer and received care at The Ohio State University Thoracic Oncology Center, and resided in Franklin County or 6 adjacent counties. During the pre-cohort time period, access to palliative care was available at a stand-alone palliative care clinic. Palliative care intervention in both cohorts included symptom assessment and management, advance care planning, and goals of care discussion as appropriate. Outcomes evaluated included rates of emergency department (ED) visits, hospital admissions, 30-day readmissions, and intensive care unit (ICU) admissions. Estimates were calculated in rates per-person-years and with Poisson regression models.
In total, 474 patients met criteria for analysis (214 patients included in the pre-cohort and 260 patients in the post-cohort). Among all patients, 52% were male and 48% were female with a median age of 65 years (range 31-92). Most patients had non-small cell lung cancer (NSCLC - 17% stage 1-2, 20% stage 3, 47% stage 4) and 16% had small cell lung cancer. The post-cohort was older [median age 66 years vs 63 years in the pre-cohort (p-value: < 0.01)]. The post-cohort had a 26% reduction in ED visits compared to the pre-cohort, controlling for age, race, marital status, sex, county, Charlson score at baseline, cancer type and stage (adjusted relative risk: aRR: 0.74, 95% CI: 0.58-0.94, p-value = 0.01). Although not statistically significant, there was a 29% decrease in ICU admissions (aRR: 0.71, 95% CI: 0.41-1.21, p-value = 0.21) and a 15% decrease in hospital admissions (aRR: 0.85, 95% CI: 0.70-1.03, p-value = 0.10). There was no difference in 30-day readmissions (aRR: 1.03, 95% CI: 0.73-1.45, p-value = 0.85).
Embedding palliative care clinics within medical oncology clinics may decrease healthcare utilization for patients with thoracic malignancies. Further evaluation of this model is warranted.
姑息治疗对晚期肺癌患者有益,但最佳的姑息治疗模式尚不清楚。我们研究了在胸科肿瘤内科“肿瘤-姑息”诊所引入姑息治疗医生前后的医疗资源利用情况。
这是一项回顾性横断面队列研究,比较了两个队列的医疗结果:“前队列”为肿瘤-姑息诊所开始日期前12个月,“后队列”为开始日期后12个月。纳入标准为新诊断为肺癌且在俄亥俄州立大学胸科肿瘤中心接受治疗,并居住在富兰克林县或相邻6个县的患者。在前队列期间,可在独立的姑息治疗诊所获得姑息治疗。两个队列的姑息治疗干预均包括症状评估与管理、预先医疗护理计划以及酌情进行的护理目标讨论。评估的结果包括急诊就诊率、住院率、30天再入院率和重症监护病房(ICU)入住率。以每人年率和泊松回归模型计算估计值。
共有474例患者符合分析标准(前队列纳入214例患者,后队列纳入260例患者)。所有患者中,52%为男性,48%为女性,中位年龄为65岁(范围31 - 92岁)。大多数患者患有非小细胞肺癌(NSCLC - 17%为1 - 2期,20%为3期,47%为4期),16%患有小细胞肺癌。后队列年龄更大[中位年龄66岁,前队列为63岁(p值:<0.01)]。与前队列相比,后队列的急诊就诊率降低了26%,在控制年龄、种族、婚姻状况、性别、县、基线查尔森评分、癌症类型和分期后(调整相对风险:aRR:0.74,95%置信区间:0.58 - 94,p值 = 0.01)。虽然无统计学意义,但ICU入住率下降了29%(aRR:0.71,95%置信区间:0.41 - 1.21,p值 = 0.21),住院率下降了15%(aRR:0.85,95%置信区间:0.70 - 1.03,p值 = 0.10)。30天再入院率无差异(aRR:1.03,95%置信区间:0.73 - 1.45,p值 = 0.85)。
在肿瘤内科诊所内设立姑息治疗诊所可能会降低胸科恶性肿瘤患者的医疗资源利用。有必要对该模式进行进一步评估。